Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Serious adverse events: death · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: death · dialysis vascular access outcomes in AVG patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: major bleeding · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: major bleeding compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: major bleeding · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events: hospitalisation · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: hospitalisation compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: hospitalisation · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: hospitalisation compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: cardiovascular events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found